Business context and reporting period
Flora Growth Corp. (Nasdaq: FLGC), an Ontario-incorporated cannabis cultivator and consumer-products company, filed this Form 20-F for the fiscal year ended December 31, 2021. The filing is an annual report, not a standalone fourth-quarter report; it does not provide clear Q4-only financial results. Financial statements are prepared under IFRS and amounts below are in U.S. dollars.
The business spans cannabis cultivation and wholesale, consumer brands, pharmaceuticals and nutraceuticals, food and beverages, and life sciences. The company reported 65.5 million common shares outstanding at year-end.
Financial results and liquidity
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $9.0 million | $0.1 million |
| Gross profit | $2.4 million | $0.1 million |
| Operating loss | $(19.0) million | $(14.3) million |
| Net loss | $(21.4) million; $(0.48) per share | $(14.3) million; $(0.47) per share |
| Operating cash flow | $(20.6) million | $(8.4) million |
| Cash at year-end | $37.6 million | $15.5 million |
| Working capital | $41.8 million | $14.9 million |
Reported gross profit includes a $72,000 unrealized gain on biological assets; gross profit before that gain was $2.353 million. Revenue was concentrated in food and beverage ($3.6 million), consumer products ($2.6 million), pharmaceuticals and nutraceuticals ($2.3 million), and corporate ($0.4 million). Cannabis cultivation generated only $3,000 of revenue.
Total assets were $85.5 million and total liabilities were $8.5 million. Year-end debt was minimal ($18,000 current and no non-current debt); lease liabilities were $1.32 million. There were no available credit facilities. Financing activities provided $58.1 million, primarily from equity offerings and warrant/option exercises; investing activities used $14.6 million.
Material changes versus the prior comparable period
- Revenue rose from $106,000 to $9.0 million, largely reflecting acquisitions, a fuller year of ownership of acquired businesses, new sales agreements, and initial Vessel results. The cannabis cultivation business remained at an early commercial stage.
- Net loss widened by about $7.0 million. Management cited expanded staffing and operating costs, IPO and follow-on offering costs, and a $2.3 million unrealized loss on a private European cannabis investment. A $1.3 million bad-debt expense also arose from expected losses on trade receivables.
- Cash increased by $22.1 million and working capital improved, principally following equity financing. At the same time, operating cash use increased to $20.6 million.
- Vessel was acquired in November 2021 for $8.0 million cash and 4.56 million shares. The company raised $16.7 million gross in its May IPO and $34.5 million gross in its November unit offering.
Outlook, commentary, risks and unusual items
Management stated that financing proceeds were expected to fund its plan of operations through 2023, while emphasizing that this depends on execution, cash availability, revenues, and factors outside the company’s control. The strategy centers on expanding production capacity, brands, geographic reach, partnerships, and acquisitions. The company did not provide quantified revenue or earnings guidance.
- Subsequent acquisition: In February 2022, Flora acquired Just Brands and High Roller Private Label for $16.0 million cash and 9.5 million shares. The agreement includes purchase-price adjustments and potential additional share consideration tied to the share price and acquired-company results. This acquisition is not included in FY 2021 results.
- Regulatory exposure: Cannabis laws vary and change across jurisdictions; marijuana remains illegal under U.S. federal law. Colombian licenses, quotas, and ongoing compliance are material to cultivation and export plans. The filing gives differing 2022 export-quota figures in different sections, so the definitive amount is unclear from the text.
- Other risks: The company has a limited operating history, recurring losses and negative operating cash flow; it depends on future financing, third-party suppliers and logistics, successful integration of acquisitions, and agricultural yields. It also cites product liability, recalls, inventory shelf life, currency exposure, competition, and uncertain consumer and regulatory acceptance.
- Legal matters: A $1.681 million provision was reported for an IPO-underwriter dispute; in April 2022, the dispute was settled for $400,000 and 700,000 shares, with a possible additional transaction fee for qualifying acquisitions agreed before May 11, 2022. Former Vessel shareholders sent a demand letter alleging misleading conduct; no lawsuit had been filed, and Flora disputed the allegations.
- Controls and accounting: The auditor issued an unqualified opinion on the IFRS financial statements. Auditors identified 2021 material weaknesses relating to goodwill impairment and purchase-price allocations, contract receivables and related revenue, and inventory procedures. Management said remediation was ongoing. The audit did not express an opinion on internal-control effectiveness.
- The company reported a $51,000 goodwill impairment in 2021. Vessel’s reported recoverable amount exceeded carrying value by only $0.3 million; management said a 0.5 reduction in the valuation revenue multiple could result in an approximately $3.1 million impairment.
Important facts for investors to verify
- Confirm the exact 2022 Colombian cannabis export quota and the status of required export approvals.
- Review receivable collections and the basis for the $1.3 million expected-credit-loss charge, including the customer concentration noted in the filing.
- Assess cash runway against the $20.6 million FY 2021 operating cash outflow, the stated funding horizon through 2023, and the cash used for the 2022 JustCBD acquisition.
- Examine the JustCBD acquisition’s audited performance, purchase-price adjustments, potential additional share issuance, and integration results.
- Track remediation of the disclosed material weaknesses and future goodwill impairment testing, particularly for Vessel.
- Review the status and potential financial impact of the VBI shareholder claims and any remaining obligations related to the underwriter settlement.